Last reviewed · How we verify
NCT05550233: DCB-LVD
Drug-coated Balloons in Big de Novo Coronary Disease
NA trial testing drug-coated balloon in Coronary Heart Disease in 240 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Beijing Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 1 October 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- drug-coated balloon
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
Sponsor
Beijing Hospital
Who can join
18 and older, any sex, with Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, multicenter, randomized controlled, open-label, non-inferiority trial. Plan to recruit 240 patients whose lesions are de novo coronary artery disease (reference vessel diameter ≥ 3.0 mm), diameter stenosis ≥ 75% with ischemic symptoms or objective evidence of ischemia (ECG, cardionuclide, or FFR), and are suitable for implantation DES or DCB. After successful preconditioning, patients were randomly assigned to two PCI treatment groups(drug-coated balloon or drug-eluted stent) in a 1:1 ratio. The safety and efficacy of drug-coated balloons in PCI treatment of de novo coronary artery lesions (reference diameter 3.0 mm and above) were evaluated by comparing the late lumen loss of two groups of subjects in 12 months.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immediate and follow-up outcomes of drug-coated balloon angioplasty in de novo long lesions on large coronary arteries.
Leone PP, Oliva A, Regazzoli D, Gitto M, et al · · 2023 · cited 23× · PMID 37670668 · DOI 10.4244/eij-d-23-00502 -
Exploring New Avenues for De Novo Coronary Artery Disease: Next Steps Forward With Drug-Coated Balloons.
Kang DO, Kim SW, Jeong YH. · · 2024 · cited 2× · PMID 39101108 · DOI 10.1016/j.jacasi.2024.05.006 -
A New Frontier for Drug-Coated Balloons: Treatment of "De Novo" Stenosis in Large Vessel Coronary Artery Disease.
Sciahbasi A, Mazza TM, Pidone C, Samperi S, et al · · 2024 · cited 1× · PMID 38592181 · DOI 10.3390/jcm13051320 -
The longest way round is the shortest way home: drug-coated balloons for long lesions in large coronary arteries.
Gonzalo N, Shabbir A. · · 2023 · cited 1× · PMID 38105718 · DOI 10.4244/eij-e-23-00043 -
Drug-coated balloons in complex large-vessel coronary artery disease: a comprehensive review of current evidence and future perspectives.
Gitto M, Gabrielli A, Leone PP, Sanz-Sanchez J, et al · · 2026 · PMID 41815903 · DOI 10.3389/fcvm.2026.1731952 -
Contemporary Percutaneous Coronary Intervention in Diabetic Patients.
Tartaglia F, Filiberti G, Bernardini V, Gitto M, et al · · 2025 · PMID 41524061 · DOI 10.31083/rcm44861
Verify or expand the search:
- PubMed search for NCT05550233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of drug-coated balloon
Trials testing the same drug.
- NCT07162792 — The Safety and Efficacy of New-Generation BRS vs. DCB for De Novo Large Coronary Artery Lesions: A Prospective RCT · NA · not yet recruiting
- NCT07014475 — Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI · not yet recruiting
- NCT06104033 — Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease · recruiting
- NCT05616520 — Treatment of Complex Femoropopliteal Artery Lesions Using Drug-coated PTA Balloon · unknown
- NCT04778969 — Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database · unknown
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
Other Beijing Hospital trials
Trials by the same sponsor.
- NCT07523724 — Screening and Management of Adults With Asthma and Allergic Diseases · NA · not yet recruiting
- NCT07398430 — Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea · not yet recruiting
- NCT07295665 — External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease · not yet recruiting
- NCT07143851 — Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases · not yet recruiting
- NCT06955819 — GUTPROH: Probiotic-Herbal Formula for Self-Reported Constipation in Community Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05550233 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Hospital
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05550233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing